Original Article

You have full text access to this OnlineOpen article

Advanced seminoma—Treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease

A single-institution experience in 145 patients

  1. Dany Gholam M.D.1,
  2. Karim Fizazi M.D.1,
  3. Marie-Jose Terrier-Lacombe M.D.2,
  4. Pascale Jan B.Sc.3,
  5. Stephane Culine M.D.1,
  6. Christine Theodore M.D.1,†,*

Article first published online: 8 JUL 2003

DOI: 10.1002/cncr.11574

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 745–752, 15 August 2003

Additional Information

How to Cite

Gholam, D., Fizazi, K., Terrier-Lacombe, M.-J., Jan, P., Culine, S. and Theodore, C. (2003), Advanced seminoma—Treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease. Cancer, 98: 745–752. doi: 10.1002/cncr.11574

Author Information

  1. 1

    Department of Medicine, Institut Gustave Roussy, Villejuif, France

  2. 2

    Department of Pathology, Institut Gustave Roussy, Villejuif, France

  3. 3

    Department of Statistics, Institut Gustave Roussy, Villejuif, France

  1. †

    Fax: (011) 33-142115238

*Department of Medicine, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 8 JUL 2003
  3. Manuscript Accepted: 13 MAY 2003
  4. Manuscript Revised: 18 APR 2003
  5. Manuscript Received: 25 NOV 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (214K)

REFERENCES

  • 1
    Willan B, McGowan D. Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys. 1985; 11: 1769–1775.
  • 2
    Fossa S, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys. 1989; 16: 383–388.
  • 3
    Gregory C, Peckham M. Results of radiotherapy for stage II testicular seminoma. Radiother Oncol. 1986; 6: 285–292.
  • 4
    Warde P, Gospodarowicz M, Panzarella T, et al. Management of Stage II seminoma. J Clin Oncol. 1998; 16: 290–294.
  • 5
    Polansky SM, Barwick KW, Ravin CE. Primary mediastinal seminoma. Am J Radiol. 1979; 12: 17–21.
  • 6
    Fizazi K, Culine S, Droz JP, et al. Initial management of primary mediastinal seminoma: radiotherapy or cisplatin-based chemotherapy? Eur J Cancer. 1998; 34: 347–352.
  • 7
    Friedman E, Garnick M, Stomper P, et al. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol. 1985; 3: 1325–1332.
  • 8
    Loehrer P, Birch R, Williams S, Einhorn L. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol. 1987; 5: 1212–1220.
  • 9
    Logothetis CJ, Samuels ML, Ogden SL, et al. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term follow-up in 52 patients. J Urol. 1987; 138: 789–794.
  • 10
    Mencel P, Motzer R, Bajorin D, et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol. 1994; 12: 120–126.
  • 11
    [No authors listed.] International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Consensus Group. J Clin Oncol. 1997; 15: 594–603.
  • 12
    Culine S, Theodore C, Droz JP, et al. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience. Eur J Cancer. 1998; 34: 353–358.
  • 13
    Fossa SD, Droz JP, Stoter G, et al. Cisplatin, vincristine, and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer. 1995; 71: 619–624.
  • 14
    Miller K, Loehrer P, Einhorn L. Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma. J Clin Oncol. 1997; 15: 1427–1431.
  • 15
    Motzer R, Mazumdar M, Bajorin D, Bosl G. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997; 15: 2546–2552.
  • 16
    Grill J, Kalifa C, Droz F, et al. A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A Phase II study. Pediatr Neurosurg. 1996; 25: 7–12.
  • 17
    Lotz JP, Andre T, Donsimoni R, et al. High-dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer. 1995; 76: 154–155.
    Direct Link:
  • 18
    Fossa SD, Oliver RTD, Stenning SP, et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer. 1997; 33: 1380–1387.
  • 19
    Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cisplatinum based combination chemotherapy or carboplatin (JM8). Br J Cancer. 1985; 52: 7–13.
  • 20
    Tjulandin SA, Khlebnov AV, Nasirova RJ, et al. VAB-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic seminoma patients: the USSR experience. Ann Oncol. 1991; 2: 667–672.
  • 21
    Bokemeyer C, Kollmannsberger C, Flechon A, et al. Prognostic factors in patients with advanced metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a meta-analysis of prospective European trials [abstract 740]. Proc Am Soc Clin Oncol. 2002; 21: 186.
  • 22
    Bobba VS, Mittal BB, et al. Classical and anaplastic seminoma: difference in survival. Radiology. 1988; 167: 849–852.
  • 23
    Aubry F, Satie AP, Rioux-Leclercq N, et al. MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer. 2001; 92: 2778–2785.
    Direct Link:
  • 24
    Tickoo SK, Hutchinson B, Motzer RJ, et al. Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with specific reference to seminomas with atypical features. Int J Surg Pathol. 2002; 10: 23–32.
  • 25
    Vuky J, Tickoo S, Bajorin D, Bosl G, Motzer R. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol. 2002; 20: 297–301.
  • 26
    Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol. 1994; 12: 2277–2283.
  • 27
    Motzer RJ, Mazumbar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000; 18: 1173–1180.
  • 28
    Rosti G, Pico JL, Wandt H, et al. High-dose therapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors; first results of a prospective randomized trial of the European Group for Blood and Marrow Transplantation: IT-94 study. Proc Am Soc Clin Oncol. 2002; 21: 180.
  • 29
    Rick O, Siegert W, Schwella N, Krusch A, Beyer J. High-dose chemotherapy as salvage treatment for seminoma. Bone Marrow Transplant. 2002; 30: 157–160.
View Full Article (HTML) Get PDF (214K)